Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Eye2Gene explores the use of AI to determine which genetic condition is causing a patient’s inherited retinal disease, by examining eye scans.

retina

Eye2Gene is led by Dr Nikolas Pontikos at UCL, Professor Susan Downes at Oxford and Savita Madhusudhan at Liverpool.

The Department of Health and Social Care awarded £1.3M to phase 2 of the Eye2Gene project as part of its Artificial Intelligence in Health & Care Award. This Award makes £140 million available over four years to accelerate the testing and evaluation of artificial intelligence technologies which meet the aims set out in the NHS Long Term Plan.

The Award aims to increase the impact of AI-driven technologies to help solve clinical and operational challenges across the NHS and care settings. It will speed up the most promising technologies through the regulatory process by building an evidence base to demonstrate the effectiveness and safety of AI-driven technologies in health and social care.

With more than 300 possible genetic causes of inherited retinal disease, requiring differing management or treatment options, swift diagnosis is crucial. The Eye2Gene technology has been developed at UCL and Moorfields, and will be validated at Oxford University Hospital and the other sites.

The clinical safety officer, Dr Mital Shah from Oxford, will be responsible for overseeing the safety and efficacy of Eye2Gene in a retrospective observational evaluation on clinical scans from patients with a confirmed genetic diagnosis that will be collected from the participating sites.

Phase 2 of the project starts on 1 January 2022 and will last for three years, during which Eye2Gene will be developed into a software as a medical device to be used for decision support.

Similar stories

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Royal Academy of Engineering Research Fellowship

Dr Rezvan Farahibozorg has received one of 17 Royal Academy of Engineering Research Fellowships for 2022.

Three New Professors

Many congratulations to the following members of our Department who have been awarded the title of Professor in the recent Recognition of Distinction round.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.

Finding out more about Parkinson’s by monitoring symptoms at home

Professor Chrystalina Antoniades explains how the COVID pandemic accelerated an innovation in one research project into Parkinson's Disease.